Serpin E1/PAI-1 Antibody [Alexa Fluor™ Plus 594]

• Reactivity: Hu
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor Plus 594

Serpin E1/PAI-1 Antibody [Alexa Fluor™ Plus 594] Summary

• Specificity: Detects human Serpin E1/PAI‑1 in direct ELISAs and Western blots. In direct ELISAs, approximately 15% cross-reactivity with recombinant mouse Serpin E1 is observed.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Serpin E1/PAI-1 Antibody [Alexa Fluor™ Plus 594]

• Endothelial plasminogen activator inhibitor
• Nexin
• PAI1
• PAI-1
• PAI1PAI-1
• PAISerpin E1
• PLANH1
• PLANH1plasminogen activator inhibitor 1
• serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogenactivator inhibitor type 1), member 1
• Serpin E1
• serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitortype 1), member 1

Background

As a member of the Serpin superfamily of serine protease inhibitors, Serpin E1/PAI-1 is the principal inhibitor of urokinase-type plasminogen activator (uPA) and tissue-type PA (1, 2). As important regulators of extracellular matrix remodeling, uPA and PAI-1 play a major role in many processes such as angiogenesis, tumor invasion and obesity (2-4). For example, uPA and PAI-1 are the only tumor prognostic factors validated at the highest level of evidence with regard to their clinical utility in breast cancer (5). The human PAI-1 is initially synthesized as 402 amino acid precursor with a N-terminal signal peptide (6, 7). PAI-1 may exist in one of two possible conformations, designated as active or latent (8). The purified recombinant human (rh) PAI-1 is active against rhuPA. The heterogeneity at the N-terminus of the purified rhPAI-1 has been observed before for both the recombinant and native proteins (9).

1. Silverman, G.A. et al. (2001) J. Biol. Chem. 276:33293.
2. Stefansson, S. et al. (2003) Curr. Pharm. Des. 9:1545.
3. Duffy, M.J. (2002) Clin. Chem. 48:1194.
4. Juhan-Vague, I. et al. (2003) J. Thromb. Haemost. 1:1575.
5. Harbeck, N. et al. (2002) Clin. Breast Cancer 3:196.
6. Pannekoek, H. et al. (1986) EMBO J. 5:2539.
7. Ginsburg, D. et al. (1986) J. Clin. Invest. 78:1673.
8. Wang, Z. et al. (1996) Biochemistry 35:16443.
9. Stromqvist, M. et al. (1994) Protein Expr. Purif. 5:309.  

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.